The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Open accessAbstract
Overexpression of MYC is a hallmark of many human cancers. The MYC oncogene has long been thought to execute its neoplastic functions by acting as a classic transcription factor, deregulating the expression of a large number of specific target genes. However, MYC’s influence on many of these target genes is rather modest and there is little overlap between MYC regulated genes in different cell types, leaving many mechanistic questions unanswered. Recent advances in the field challenge the dogma further, revealing a role for MYC that extends beyond the traditional concept of a sequence-specific transcription factor. In this article, we review MYC’s function as a regulator of the cancer epigenome and transcriptome. We outline our current understanding of how MYC regulates chromatin structure in both a site-specific and genome-wide fashion, and highlight the implications for therapeutic strategies for cancers with high MYC expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 4×
“Loss-of-function mutations in EZH2, EED, and SUZ12 have been reported for T-cell acute lymphoblastic leukemia (T-ALL) and MDS [99,100], suggesting a role as tumor suppressors in specific hematological malignancies.”
BackgroundInfluentialOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 4×
“Loss-of-function mutations in EZH2, EED, and SUZ12 have been reported for T-cell acute lymphoblastic leukemia (T-ALL) and MDS [99,100], suggesting a role as tumor suppressors in specific hematological malignancies.”
BackgroundInfluentialTan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · cited 1×
“EZH2 proves to be a good therapeutic target in MYC-positive cancers; however, DZNeP lacks the needed specificity to be a promising strategy in clinical applications [172,173].”
BackgroundYeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins
McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D., & Cole, M. D. (1998) · Cell · doi:10.1016/s0092-8674(00)81479-8 · Cited by 693
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc
McMahon, S. B., Wood, M. A., & Cole, M. D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.556-562.2000 · Cited by 494 · cited 5×
“to the transformation activity of MYC through interactions with MB I and II [26,27].”
BackgroundInfluentialHumphrey, G. W., Wang, Y., Russanova, V. R., Hirai, T., Qin, J., Nakatani, Y., & Howard, B. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007372200 · Cited by 331 · cited 7×
“The notion that MYC upregulates the HAT, GCN5, and HDAC2 raises questions regarding their differential specificity and function on a genome-wide level.”
BackgroundInfluentialInteraction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC
Thomas, L. R., Wang, Q., Grieb, B. C., Phan, J., Foshage, A. M., Sun, Q., Olejniczak, E. T., Clark, T., Dey, S., Lorey, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.028 · Cited by 310 · cited 13×
“For example, how is WDR5 itself tethered to chromatin, and is MYC competing with other WDR5-binding partners such as MLL?”
BackgroundInfluentialFiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G. T., Liu, K., Iyer, S. P., Bearss, D., & Bhalla, K. N. (2014) · Leukemia · doi:10.1038/leu.2014.119 · Cited by 284
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia
Grebien, F., Vedadi, M., Getlik, M., Giambruno, R., Grover, A., Avellino, R., Skucha, A., Vittori, S., Kuznetsova, E., Smil, D., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1859 · Cited by 284 · cited 1×
“OICR-9429 antagonizes the WDR5–MLL interaction, selectively inhibited proliferation, and induced differentiation in human AML cells [191]; in contrast, MM-401 targets the MLL1 H3K4 methyltransferase activity and was able to inhibit MLL1 activity by blocking MLL1–WDR5 interaction and complex assembly, specifically bloc…”
BackgroundTumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J. R., Tabor, V., Aichele, P., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.043 · Cited by 184 · cited 2×
“SUV39H1 deficiency results in loss of H3K9me3, increased genomic instability, and the development of B- and T- cell lymphomas in mice, indicating its important role for preventing malignant transformation [127].”
BackgroundBioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors
Dingar, D., Kalkat, M., Chan, P.-K., Srikumar, T., Bailey, S. D., Tu, W. B., Coyaud, E., Ponzielli, R., Kolyar, M., Jurisica, I., et al. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2014.09.029 · Cited by 131 · cited 1×
“WDR5 was found to directly interact with MYC via the MB III motif in the central region [145,146], suggesting a scenario in which WDR5 mediates the recruitment of MYC to active chromatin loci.”
Background
Cited by
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance
Weiss, F., Lauffenburger, D., & Friedl, P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00427-0 · Cited by 293
Uzdensky, A. B. (2019) · Apoptosis · doi:10.1007/s10495-019-01556-6 · Cited by 292
Metadata
- Authors
- Poole, C. J., & Van Riggelen, J.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2017-05-13
- Volume
- 8
- Issue
- 5
- Pages
- 142
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W2612646577
- Cited by
- 183
- References
- 20
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.